Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: Robust gene signature correlates with radiotherapy outcome in patients and xenografts.
Linge A, Patil S, Grosser M, Lohaus F, Gurtner K, Kemper M, Gudziol V, Haim D, Nowak A, Tinhofer I, Zips D, Guberina M, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Boeke S, Gani C, Jöhrens K, Baretton GB, Löck S, Baumann M, Krause M; DKTK-ROG. Linge A, et al. Among authors: gudziol v. Radiother Oncol. 2024 Feb;191:110055. doi: 10.1016/j.radonc.2023.110055. Epub 2023 Dec 16. Radiother Oncol. 2024. PMID: 38109944 Free article.
Corrigendum to "Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens" [Radiother. Oncol. 137 (2019) 24-31].
Meneceur S, Löck S, Gudziol V, Hering S, Bütof R, Rehm M, Baumann M, Krause M, von Neubeck C. Meneceur S, et al. Among authors: gudziol v. Radiother Oncol. 2023 Jun;183:109619. doi: 10.1016/j.radonc.2023.109619. Epub 2023 Mar 29. Radiother Oncol. 2023. PMID: 37001220 No abstract available.
A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT.
Patil S, Linge A, Hiepe H, Grosser M, Lohaus F, Gudziol V, Kemper M, Nowak A, Haim D, Tinhofer I, Budach V, Guberina M, Stuschke M, Balermpas P, Grün JV, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Boeke S, Zips D, Jöhrens K, Baretton GB, Baumann M, Krause M, Löck S, On Behalf Of The Dktk-Rog. Patil S, et al. Among authors: gudziol v. Cancers (Basel). 2022 Jun 20;14(12):3031. doi: 10.3390/cancers14123031. Cancers (Basel). 2022. PMID: 35740697 Free PMC article.
Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy.
Patil S, Linge A, Grosser M, Lohaus F, Gudziol V, Kemper M, Nowak A, Haim D, Tinhofer I, Budach V, Guberina M, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Boeke S, Zips D, Baretton GB, Baumann M, Krause M, Löck S; DKTK-ROG. Patil S, et al. Among authors: gudziol v. Radiother Oncol. 2022 Jun;171:91-100. doi: 10.1016/j.radonc.2022.04.006. Epub 2022 Apr 13. Radiother Oncol. 2022. PMID: 35429503
Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG.
Löck S, Linge A, Lohaus F, Ebert N, Gudziol V, Nowak A, Tinhofer I, Kalinauskaite G, Guberina M, Stuschke M, Balermpas P, von der Grün J, Grosu AL, Debus J, Ganswindt U, Belka C, Peeken JC, Combs SE, De-Colle C, Zips D, Baretton GB, Krause M, Baumann M; DKTK-ROG. Löck S, et al. Among authors: gudziol v. Radiother Oncol. 2022 Apr;169:8-14. doi: 10.1016/j.radonc.2022.02.009. Epub 2022 Feb 16. Radiother Oncol. 2022. PMID: 35182686
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine.
Richter S, Qiu B, Ghering M, Kunath C, Constantinescu G, Luths C, Pamporaki C, Bechmann N, Meuter L, Kwapiszewska A, Deutschbein T, Nölting S, Peitzsch M, Robledo M, Prejbisz A, Pacak K, Gudziol V, Timmers HJLM, Eisenhofer G. Richter S, et al. Among authors: gudziol v. Endocr Relat Cancer. 2022 Mar 21;29(4):213-224. doi: 10.1530/ERC-21-0359. Endocr Relat Cancer. 2022. PMID: 35171114 Free PMC article.
Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy.
Patil S, Tawk B, Grosser M, Lohaus F, Gudziol V, Kemper M, Nowak A, Haim D, Tinhofer I, Budach V, Guberina M, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Boeke S, Zips D, Baretton GB, Baumann M, Krause M, Löck S, Linge A; DKTK-ROG. Patil S, et al. Among authors: gudziol v. Radiother Oncol. 2022 Feb;167:300-307. doi: 10.1016/j.radonc.2021.12.049. Epub 2022 Jan 6. Radiother Oncol. 2022. PMID: 34999136
Lipidomic profile of human nasal mucosa and associations with circulating fatty acids and olfactory deficiency.
Khoury S, Gudziol V, Grégoire S, Cabaret S, Menzel S, Martine L, Mézière E, Soubeyre V, Thomas-Danguin T, Grosmaitre X, Bretillon L, Berdeaux O, Acar N, Hummel T, Le Bon AM. Khoury S, et al. Among authors: gudziol v. Sci Rep. 2021 Aug 18;11(1):16771. doi: 10.1038/s41598-021-93817-1. Sci Rep. 2021. PMID: 34408170 Free PMC article. Clinical Trial.
Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
Wallace PW, Conrad C, Brückmann S, Pang Y, Caleiras E, Murakami M, Korpershoek E, Zhuang Z, Rapizzi E, Kroiss M, Gudziol V, Timmers HJ, Mannelli M, Pietzsch J, Beuschlein F, Pacak K, Robledo M, Klink B, Peitzsch M, Gill AJ, Tischler AS, de Krijger RR, Papathomas T, Aust D, Eisenhofer G, Richter S. Wallace PW, et al. Among authors: gudziol v. J Pathol. 2020 Aug;251(4):378-387. doi: 10.1002/path.5472. Epub 2020 Jul 1. J Pathol. 2020. PMID: 32462735 Free PMC article.
68 results